A Phase 4 interventional study of mRNA-1273 (Moderna COVID-19 vaccine) in COVID-19, sponsored by Tor Biering-Sørensen. Completed at 2 sites in Denmark. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Tor Biering-Sørensen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one has the largest enrollment, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 35th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 50 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41,060 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.
Tor Biering-Sørensen has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.
The study is a pragmatic, registry-based, open-label, individually randomized trial. The Danish nationwide administrative health registries will be used for data collection including baseline information, follow-up data, and safety monitoring. The study aims to randomize a total of 285,000 participants. Participants will be individually randomized 1:1 to receive either a COVID-19 vaccine or no COVID-19 vaccine. The study is designed to assess the vaccine effectiveness of the COVID-19 vaccine vs. no COVID-19 vaccine on the risk of medically attended COVID-19 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions that increase the risk of severe COVID-19, which will be assessed through self-reporting. These medical conditions include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COVID-19 vaccine single injection at day 0
Biological: mRNA-1273 (Moderna COVID-19 vaccine)
Control arm, no COVID-19 vaccine
For this arm, the current variant formulation of Spikevax (mRNA-1273) vaccine will be used.
Medically attended COVID-19
Defined as a positive PCR test for SARS-CoV-2 or hospitalization for COVID-19-related respiratory tract disease
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
COVID-19-related hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
COVID-19-related respiratory tract disease hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
COVID-19-related cardio-respiratory disease hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
All-cause respiratory tract disease hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
All-cause cardio-respiratory hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
All-cause lower respiratory tract disease hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
All-cause hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
COVID-19 death
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
All-cause death
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
COVID-19-related hospitalization (alternate definition)
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Laboratory-confirmed COVID-19
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Total length of hospital stays due to COVID-19-related respiratory tract disease
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Composite of hospitalization for COVID-19 or pneumonia (ICD-10 codes only)
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Hospitalization for any cardiovascular disease
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Hospitalization due to any infectious disease
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Hospitalization requiring mechanical ventilation
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
In-hospital mortality
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Cardio-respiratory mortality
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Respiratory mortality
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Cardiovascular mortality
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Intensive care unit admission
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Laboratory-confirmed COVID-19 hospitalization
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Any hospital contact associated with laboratory-confirmed COVID-19
Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Plan to share: Yes — In this trial, baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Aug 2026, 8 months.
Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 8 months is below that.
Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273
Tor Biering-Sørensen